Cargando…

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

PURPOSE: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. METHODS: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dong Wook, Chung, Weon Kuu, Shin, Dongoh, Hong, Seongeon, Park, Sung Ho, Park, Sung-Yong, Chung, Kwangzoo, Lim, Young Kyung, Shin, Dongho, Lee, Se Byeong, Lee, Hyun-ho, Yoon, Myonggeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599921/
https://www.ncbi.nlm.nih.gov/pubmed/23452670
http://dx.doi.org/10.1186/1748-717X-8-47
_version_ 1782475560597848064
author Kim, Dong Wook
Chung, Weon Kuu
Shin, Dongoh
Hong, Seongeon
Park, Sung Ho
Park, Sung-Yong
Chung, Kwangzoo
Lim, Young Kyung
Shin, Dongho
Lee, Se Byeong
Lee, Hyun-ho
Yoon, Myonggeun
author_facet Kim, Dong Wook
Chung, Weon Kuu
Shin, Dongoh
Hong, Seongeon
Park, Sung Ho
Park, Sung-Yong
Chung, Kwangzoo
Lim, Young Kyung
Shin, Dongho
Lee, Se Byeong
Lee, Hyun-ho
Yoon, Myonggeun
author_sort Kim, Dong Wook
collection PubMed
description PURPOSE: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. METHODS: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). RESULTS: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. CONCLUSIONS: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.
format Online
Article
Text
id pubmed-3599921
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35999212013-03-23 Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer Kim, Dong Wook Chung, Weon Kuu Shin, Dongoh Hong, Seongeon Park, Sung Ho Park, Sung-Yong Chung, Kwangzoo Lim, Young Kyung Shin, Dongho Lee, Se Byeong Lee, Hyun-ho Yoon, Myonggeun Radiat Oncol Research PURPOSE: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. METHODS: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). RESULTS: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. CONCLUSIONS: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT. BioMed Central 2013-03-04 /pmc/articles/PMC3599921/ /pubmed/23452670 http://dx.doi.org/10.1186/1748-717X-8-47 Text en Copyright ©2013 Kim et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kim, Dong Wook
Chung, Weon Kuu
Shin, Dongoh
Hong, Seongeon
Park, Sung Ho
Park, Sung-Yong
Chung, Kwangzoo
Lim, Young Kyung
Shin, Dongho
Lee, Se Byeong
Lee, Hyun-ho
Yoon, Myonggeun
Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title_full Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title_fullStr Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title_full_unstemmed Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title_short Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
title_sort risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599921/
https://www.ncbi.nlm.nih.gov/pubmed/23452670
http://dx.doi.org/10.1186/1748-717X-8-47
work_keys_str_mv AT kimdongwook riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT chungweonkuu riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT shindongoh riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT hongseongeon riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT parksungho riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT parksungyong riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT chungkwangzoo riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT limyoungkyung riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT shindongho riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT leesebyeong riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT leehyunho riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer
AT yoonmyonggeun riskofsecondcancerfromscatteredradiationofintensitymodulatedradiotherapieswithlungcancer